Periodic Benefit-Risk Evaluation Report PBRER -With Template

Learn to deliver a comprehensive, concise, and critical PBRER by analyzing new safety and efficacy data within the cumulative context since its IBD, assessing impact on the benefit-risk balance.

This lecture outlines global principles for pbrer writing: one fiber per active substance, separate pbrers for multiple formulations or fixed-dose combos, and responsibilities and reference safety information.

Explore the PBRER format, core sections and dependencies, and the template guidance for the title page, executive summary, and table of contents.

Explore the structure of the PBRER, from introduction to integrated benefit-risk analysis, including regulatory data, exposure, safety signals, and risk management.

Summarize the five standard PBR appendices, including RSI linkage, 2.1 serious adverse events, 2.2 post-marketing data, safety signals (appendix 3), study listings, and appendix 5 sources, with EMA regional addenda.

Compare PSR and PBRER to reveal differences in guideline revisions, section counts, and executive summary presence, while highlighting integrated benefit-risk evaluation and new safety data context.

Introduce section 1 of the PBRER, detailing reporting interval, start date, and data lock point, and summarize the product's mechanism of action, indications, dosages, routes, and safety data exchange agreements.

Outlines the worldwide marketing authorization status in PBR section two, detailing first-authorization date, country-specific indications and dosages, and the recommended tabular presentation of approvals and withdrawals.

Outline the section three actions taken for safety reasons in the pbrer, covering recalls, suspensions, risk minimization measures, labeling updates, and health professional communications via post-authorisation safety studies.

Explore section four of the PBRER, detailing changes to the reference safety information including contraindications, warnings and precautions, adverse reactions, drug interactions, and updated safety data.

Explore section 5 of the PBRER, detailing estimated exposure and use patterns across clinical trials and post-marketing data, including cumulative exposure and special-population insights from pharmacovigilance.

Learn to draft section 5 of a PBRER, detailing estimated exposure and use patterns through cumulative trial exposure, post-marketing exposure, and methodology using sales data and defined daily dose.

Summarizes section 6 data in summary tabulations for PBRER, using Icpsr safety database data for clinical trials and post-marketing, detailing serious and non-serious adverse events by MedDRA, SOC, and PT.

Learn how section 6 data are presented in the PBRER template, including 6.1 MedDRA version, 6.2 cumulative serious adverse events from trials, and 6.3 cumulative and interval post-marketing tabulations.

This section distills safety findings from NIH sponsored interventional trials, outlining data sources, data lock points, safety signals, and subsection workflows from 7.1 to 7.5, plus appendix four trial listings.

Draft section seven of the PBRER by detailing significant safety findings from clinical trials, including study titles, numbers, patient enrollment, and interim or long-term results.

Explore section 8 of the pbrer, presenting safety findings from non-interventional studies using real-world data. Identify study types and objectives, and outline appendix 4b listings and risk minimization evaluation cross-references.

Explore section 11 literature, where global and local searches identify new significant safety findings, including unpublished manuscripts, for aggregate reports and icsrs, with attention to class effects and cross-references.

Present section 12 use of safety information from other periodic reports, including DSR and licensee partner papers, for fixed combination product, monotherapy, and multiple indications under safety data exchange agreements.

Present lack of efficacy data from controlled clinical trials for products targeting serious or life-threatening diseases, emphasizing data from the clinical team and associated cardiovascular adverse events in section 13.

Discover how section 14 compiles late breaking information after the data lock point, covering clinically significant new publications, follow-up data, safety actions, and label updates.

Explore signal management in pharmacovigilance, from detection and validation to assessment and prioritization of safety signals, guiding label updates and risk mitigation.

Explore section 15 of the PBRER, detailing how to classify and present new, ongoing, and closed signals using validated data from pharmacovigilance, ICSR, and literature.

Explore how the flow chart shows new safety data from multiple information sources updating signal and risk classifications, guiding presentation in pbrer sections 15, 16.2, 16.3, 16.4, 18.2, and 19.

Draft section 15 of the PBRER to present validated, ongoing, and closed signals with appendix three cross-references, and manage section 15.2 health authority requests with safety evaluations.

Explore section 16 of PBRER on signal and risk evaluation, covering safety concerns, closed signals, risk information, characterization, and effectiveness checks for risk minimization.

Explain 16.1 safety concerns by detailing important identified risks, potential risks, and missing information present at the reporting interval start date.

Describe how section 16.2 presents signal evaluation, detailing closed refuted signals and closed confirmed signals, with important and non important risks and a focus on causality.

Explain how section 16.3 evaluates new information during the reporting interval to update risk characterization, focusing on changes in frequency, severity, mechanism, and reversibility across risk categories.

Characterize risk by compiling cumulative data across trials and post-marketing, using frequency categories from very common to very rare, plus seriousness, risk factors, and mitigation.

Examine how risk minimization measures, including routine product label updates and additional actions like educational materials, are implemented and evaluated for effectiveness in reducing adverse drug reactions.

Explore how section 16 in the pbrer template drafts signal and risk evaluations, including safety concerns, risk characterization, and assessed effectiveness of risk minimization measures.

Draft section 17 of the PBRER by detailing baseline efficacy and effectiveness from approved indications. Identify new information during the reporting interval for 17.2, including new indications and publications.

Section 18 of the PBRER guides integrated benefit-risk analysis for authorized indications, covering medical need, alternatives, and a structured evaluation of benefits, risks, and risk management.

Draft section 18 of the PBRER using sections 16.4 and 17.3 to present medical need, alternatives, and a benefit-risk analysis. Include epidemiological data and real-world evidence to support benefits.

Section 19 of the PBR draws conclusions and planned actions by the marketing authorization holder, evaluating new safety and efficacy information to refine the benefit-risk profile and propose label updates.

Drafts section 19 guidance to evaluate cumulative and interval safety data, confirm a favorable benefit–risk profile, and propose label changes or ARMM measures as needed.

Review health authority processes for aggregate safety reports and PBRER assessment reports, provide feedback, and issue requests for cumulative safety analyses and potential label changes.

Explain how the EMA uses the PSUSA procedure for medicines, enabling a single assessment by Prac of multiple papers, with preliminary and updated reports, leading to final recommendations.

Learn how post-marketing requirements drive health authority requests in section 15.2 to monitor safety topics, request cumulative analyses of adverse events using IBD data, and update labels and safety studies.

Plan and align cross-functional teams for pbrer preparation, outlining pre-dlp kickoff and safety strategy meetings, data requests for regulatory, labeling, exposure, and clinical study data.

Explore the PBRER authoring workflow, detailing data compilation from regulators, biostatisticians, and clinical teams, section drafting, safety summaries, signal evaluation, and quality control for a compliant report.